Ziphius Vaccines Raises €29.3M in Oversubscribed Series A Financing

  • Original €20M target oversubscribed
  • Funds to support further development of proprietary saRNA platform based on positive preclinical proof-of-concept data of ZIP-1642
  • Established new offices in Merelbeke, Ghent to support for rapid expansion

May 25, 2021 at 08:00 AM CET

Ziphius Vaccines (the “Company” or “Ziphius”), a self-amplifying RNA (saRNA) company developing transformative vaccines for existing and emerging infectious diseases, today announced the closing of its Series A financing round. The Company raised a total of €24.3 million in equity through a strong commitment of Belgian Family Offices and an additional €5 million convertible loan.

Earlier this year, Ziphius announced positive preclinical proof-of-concept data of ZIP-1642, its SARS-CoV-2 vaccine candidate. The data indicated a stronger viral neutralization potential compared to traditional mRNA vaccines and a broader layered immune response. Additionally, the platform contains the ability to quickly respond to future variants.

Proceeds from the financing will be used to advance ZIP-1642 into the clinic and further develop Ziphius’ proprietary pipeline of infectious diseases.

Chris Cardon, CEO of Ziphius Vaccines, commenting on today’s announcement, stated:
“The success of this financing round reflects the compelling proposition of our platform and compounds. With our current cash resources, we are now well-positioned to execute our ambitious business plan, designed to deliver significant stakeholder value over the next three years. I would like to welcome all new investors and thank the existing investors for their continued support in our mission to change the game in vaccination.”

“I am very pleased to support Ziphius in this Series A round and to help them advance their broad pipeline of saRNA based vaccine candidates through preclinical and early-clinical trials”, said Annie Vereecken, cornerstone investor and serial biotech entrepreneur. “The Company has shown tremendous progress since inception in 2019 and I truly believe that Ziphius’ saRNA platform is based on an innovative technology that has the potential to prevent us from emerging infectious diseases.”

Ziphius Vaccines is developing a proprietary, next generation, saRNA platform. Due to its plug-and-play features – RNA is able to code for any proteins of interest – this platform provides the ideal technology to develop vaccines against rapidly emerging pathogens. With this technology, Ziphius aims to develop best-in-class vaccines that provide high safety profiles and broad immune responses.

In order to support their rapid expansion, Ziphius recently moved to new laboratory and office spaces in Merelbeke.

About Ziphius Vaccines
Ziphius Vaccines NV is a self-amplifying RNA company developing transformative vaccines for infectious diseases and protein replacement, in order to create a new generation of medicines. The Company has a portfolio of next generation vaccine candidates targeting a wide range of infectious diseases.

Headquartered in Ghent, Belgium, Ziphius Vaccines currently has strategic partnerships with experienced executives in the pharmaceutical industry that bring over 100 years of combined expertise in drug development.

To learn more, visit www.ziphius.org

Contact:

Hendrik Thys
Investor Relations Manager
Ziphius Vaccines
Hendrik.Thys@ziphius.org